Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion
Authors:
- 2 October 2009
- journal article
- Published by Springer Nature in Eye
- Vol. 23 (11) , 2023-2033
Abstract
Purpose Design Methods Results ConclusionKeywords
This publication has 49 references indexed in Scilit:
- Intravitreal bevacizumab (Avastin(R)) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trialBritish Journal of Ophthalmology, 2008
- Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusionEye, 2008
- INTRAVITREAL BEVACIZUMAB INJECTIONS FOR TREATMENT OF CENTRAL RETINAL VEIN OCCLUSIONRetina, 2007
- INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONRetina, 2007
- INTRAVITREAL TRIAMCINOLONE ACETONIDE TREATMENT OF MACULAR EDEMA ASSOCIATED WITH CENTRAL RETINAL VEIN OCCLUSIONRetina, 2006
- Pathogenesis of Macular Edema With Branch Retinal Vein Occlusion and Intraocular Levels of Vascular Endothelial Growth Factor and Interleukin-6American Journal of Ophthalmology, 2005
- Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot studyActa Ophthalmologica Scandinavica, 2005
- Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndromeAmerican Journal of Ophthalmology, 2004
- Pathophysiology and hemodynamics of branch retinal vein occlusionOphthalmology, 1999
- MACULAR OEDEMA AND RETINAL BRANCH VEIN OCCLUSIONAustralian and New Zealand Journal of Ophthalmology, 1980